Delving into the Latest Updates on Bio-Pharm Solutions Co. Ltd. with Synapse

Overview

Basic Info

Introduction

Bio-Pharm Solutions (B-PS) is a new drug developer specializing in the central nervous system (CNS) and rare diseases. It is a fast-growing company that aims to become a specialty pharmaceutical company in the global market. Bio-Pharm Solutions is developing new drugs that meet global standards and conducting global clinical trials approved by US FDA and EMA with the CEO, who have successfully developed several global new drugs, playing a central role from the stages of discovery to clinical trials.

Tags

Nervous System Diseases

Other Diseases

Neoplasms

Small molecule drug

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Nervous System Diseases	12
Neoplasms	4
Endocrinology and Metabolic Disease	3

Top 5 Drug Type	Count

Small molecule drug	13

Top 5 Target	Count

mGluRs(Metabotropic glutamate receptor)	1

The ezrin-radixin-moesin (ERM) proteins are a family of membrane-associated proteins known to play roles in cell-shape determination as well as in signaling pathways. We have previously shown that amphetamine decreases phosphorylation levels of these proteins in the nucleus accumbens (NAcc), an important neuronal substrate mediating rewarding effects of drugs of abuse. In the present study, we further examined what molecular pathways may be involved in this process. By direct microinjection of LY294002, a PI3 kinase inhibitor, or of S9 peptide, a proposed GSK3β activator, into the NAcc core, we found that phosphorylation levels of ERM as well as of GSK3β in this site are simultaneously decreased. These results indicate that ERM proteins are under the regulation of Akt-GSK3β signaling pathway in the NAcc core. The present findings have a significant implication to a novel signal pathway possibly leading to structural plasticity in relation with drug addiction.

03 Jul 2019·NeuroReportQ4 · MEDICINE

JBPOS0101 attenuates amyloid-β accumulation and memory loss in a mouse model of Alzheimer’s disease

Q4 · MEDICINE

Article

Author: Park, Hyung Joon ; Choi, Won-Seok ; Jang, Ju Kyong ; Choi, Yong Moon

Alzheimer's disease (AD) is a major neurodegenerative disorder characterized by the accumulation of amyloid-β (Aβ) in the brain. Defects in Aβ clearance or the interference of Aβ homeostasis could result in Aβ aggregation. JBPOS0101 has been studied for its antiepileptic activity. It showed a neuroprotective effect and prevented memory deficits in lithium-pilocarpine-induced status epilepticus rats. In this study, we tested the effect of JBPOS0101 in an AD model. We showed that JBPOS0101 attenuated the accumulation of Aβ in 5XFAD mouse brains. Moreover, the treatment of JBPOS0101 rescued the deficits in learning and memory in 5XFAD mice. These data suggest that JBPOS0101 could be a potential therapeutic drug candidate for AD.

PLOS ONEQ3 · CROSS-FIELD

JBPOS0101 regulates amyloid beta, tau, and glial cells in an Alzheimer’s disease model

Q3 · CROSS-FIELD

ArticleOA

Author: Choi, Won-Seok ; Jeong, Jihoon ; Mun, Bo-Ram ; Jang, Ju Kyong ; Park, Hyung Joon ; Choi, Yong Moon

Alzheimer's disease (AD) is the most prevalent neurodegenerative disease characterized by cognitive dysfunction and memory loss as the main symptoms. The deposition of amyloid beta (Aβ) and tau hyperphosphorylation are hallmarks of AD and are major therapeutic targets. However, the exact etiology has not yet been fully elucidated; thus, no drug that cures the disease has been approved. JBPOS0101 is a phenyl carbamate compound that has been tested as a drug for epileptic diseases. In our previous study, we showed that JBPOS0101 attenuated the accumulation of Aβ as well as the deficits in learning and memory in the 5xFAD mouse model. Here, we tested the dose effect (70 or 35 mg/kg) of JBPOS0101 on the memory defect and pathological markers and further investigated the underlying mechanisms in 5xFAD mice. In the behavior tests, JBPOS0101 treatment ameliorated deficits in learning and memory. Moreover, JBPOS0101 attenuated Aβ accumulation and tau phosphorylation. The elevated phosphorylation levels of the active GSK3β form (GSK3β-y216) in 5xFAD, which are responsible for tau phosphorylation, decreased in the JBPOS0101-treated groups. Furthermore, the elevation of reactive astrocytes and microglia in 5xFAD mice was attenuated in JBPOS0101-treated groups. These data suggest that JBPOS0101 may be a new drug candidate to lessen amyloid- and tau-related pathology by regulating glial cells.

100 Deals associated with Bio-Pharm Solutions Co. Ltd.

Login to view more data

100 Translational Medicine associated with Bio-Pharm Solutions Co. Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 18 Sep 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Preclinical

11

1

Phase 1 Clinical

Phase 2 Clinical

1

5

Other

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

JBPOS-0101 ( mGluRs )	Status Epilepticus More	Phase 2
JBPOS-0501	Obesity More	Phase 1
JBPOS-0422	Epilepsy More	Preclinical
JBPOS-0552	Pain More	Preclinical
JBPOS-0607	Parkinson Disease More	Preclinical